Table 2. Baseline Characteristic Comparison Between Patients Who Completed the 16‐Week Therapy and Patients Who Dropped Out
VariableAnti–TNF‐αsDMARD
CompletersDropoutsP ValueCompletersDropoutsP Value
Patients, No.99NA1410
Drug, No. (%) Etanercept=7 (77.78)
Adalimumab=2 (32.32)
Etanercept=7 (77.78)
Adalimumab=2 (32.32)
NA Methotrexate=6 (42.85)
Leflunomide=8 (63.15)
Methotrexate=6 (60)
Leflunomide=4 (40)
0.68
Age, y47.0 [40.02–53.98]54.1 [49.59–58.63]0.0755.1 [48.60–61.55]57 [49.96–64.04]0.64
Female sex, No. (%) 7 (77.78)9 (100)0.4711 (78.57)8 (80)0.94
Erosive disease, No. (%)8 (88.89)8 (88.89)NA12 (85.71)7 (70)0.54
Rheumatoid factor, No. (%)7 (77.78)9 (100)0.4712 (85.71)7 (70)0.54
Disease duration, y10.7 [2.89–18.54]16.2 [5.76–26.64]0.299.2 [4.63–13.80]6.0 [0.94–11.06]0.35
Statins users, No. (%)4 (44.44)3 (33.33)0.501 (7.14)1 (10)0.67
Diabetes mellitus, No. (%)1 (11.11)2 (22.22)0.5000NA
Family history of CAD, No. (%)2 (22.22)00.471 (7.14)1 (10)0.67
Active smokers, No. (%)1 (11.11)1 (11.11)NA1 (7.14)2 (20)0.58
Ex‐smokers, No. (%)3 (33.33)3 (33.33)NA3 (21.43)3 (30)0.58
Weight, kg64.6 [55.11–74.09]71.9 [59.43–84.37]0.3072.6 [66.04–79.18]71.0 [64.13–77.78]0.68
Height, m1.60 [1.56–1.64]1.60 [1.55–1.66]0.971.62 [1.58–1.66]1.61 [1.55–1.66]0.68
BMI, kg/m225.3 [21.09–29.48]27.9 [23.71–32.10]0.3227.8 [25.15–30.51]27.5 [24.94–29.98]0.83
Abdominal circumference, cm90.1 [81.25–98.97]97.8 [87.94–107.61]0.2094.4 [88.80–100.06]92.4 [85.61–99.19]0.81
TC, mg/dL185.1 [158.16–212.06]201.9 [179.57–224.21]0.29185.8 [169.76–201.81]237.5 [199.96–275.04]0.004a
HDL‐C, mg/dL58.8 [45.26–72.29]52.7 [42.99–62.34]0.4152.1 [45.33–58.96]63.3 [49.69–76.91]0.08
LDL‐C, mg/dL108.6 [88.67–128.44]125.7 [108.03–143.31]0.16111.5 [99.04–123.94]134.7 [99.04–170.40]0.19
Triglycerides, mg/dL88.9 [67.88–109.90]117.8 [93.74–141.82]0.05110.8 [83.41–138.16]197.4 [7.28–387.52]0.50
TC/HDL‐C ratio3.35 [2.64–4.06]3.98 [3.28–4.68]0.163.75 [3.05–4.45]4.22 [2.52–5.93]0.77
CRP, mg/dL1.62 [0.92–2.32]3.10 [1.24–4.95]0.112.31 [1.00–3.61]1.68 [0.33–3.03]0.41
ESR, mm/h37.7 [18.64–56.70]47.3 [12.24–82.42]0.5831.8 [17.77–45.92]41.1 [25.04–57.16]0.24
DAS28‐CRP5.34 [4.22–6.47]6.57 [5.70–7.45]0.075.15 [4.43–5.88]5.06 [3.36–6.77]0.88
HAQ‐DI1.69 [1.07–2.32]2.06 [1.56–2.57]0.311.23 [0.89–1.56]1.32 [0.25–2.40]0.80
FMD%4.78 [2.13–7.42]1.40 [−6.52 to 9.30]0.252.87 [−2.17 to 7.91]3.62 [1.63–5.62]0.64
  • Values are expressed as mean [95% CIs] or percentages, as appropriate. Anti–TNF‐α indicates anti–tumor necrosis factor α; BMI, body mass index; CAD, coronary artery disease; DAS28‐CRP, Disease Activity Score of 28 joints, using C‐reactive protein (CRP); ESR, erythrocyte sedimentation rate; FMD%, flow‐mediated dilation percentage variation; HAQ‐DI, Health Assessment Questionnaire—Disability Index; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; NA, not applicable; sDMARD, synthetic disease‐modifying antirheumatic drug; TC, total cholesterol.

  • a Statistically significant.